Association of abnormal vestibular tests, excluding CDP, with demographic and clinical variables in 60 patients with psoriatic arthritis (PsA). The p values for equal odds in those who never received MTX/treated with MTX alone/initially treated with MTX and then with other DMARD alone or in combination with MTX = 0.06.
| Variables | OR (95% CI) | p |
|---|---|---|
| Age, yrs, at the time of study, by yr | 1.06 (1.00–1.12) | 0.06 |
| Age, yrs, at the time of disease diagnosis, by yr | 1.00 (0.96–1.04) | 0.93 |
| Disease duration, mo | 1.01 (1.00–1.02) | 0.21 |
| Patterns of PsA | ||
| Polyarticular | 2.87 (0.95–8.72) | 0.06 |
| Oligoarticular | 0.47 (0.15–1.45) | 0.19 |
| Mutilans | N/A | |
| Distal interphalangeal joints only | N/A | |
| Spondylitis | 0.34 (0.04–3.12) | 0.34 |
| Presence of classic cardiovascular risk factors* | 1.23 (0.41–3.71) | 0.71 |
| CRP (mg/l) at the time of disease diagnosis | 0.99 (0.95–1.03) | 0.66 |
| ESR (mm/first h) at the time of disease diagnosis | 1.01 (0.98–1.03) | 0.64 |
| CRP (mg/l) at the time of the study | 1.03 (0.95–1.12) | 0.42 |
| ESR (mm/first h) at the time of the study | 1.01 (0.96–1.06) | 0.71 |
| Patients treated with MTX alone | N/A** | |
| Initially treated with MTX and then with other DMARD+ | N/A** | |
| Patients treated with anti-TNF-α therapy# | 0.91 (0.26–3.12) | 0.88 |
↵* One or more of the following: hypertension, dyslipidemia, diabetes, obesity, and smoking history.
↵** Patients who never received MTX had normal vestibular tests, so OR could not be estimated.
↵+ Conventional DMARD (generally leflunomide and less commonly sulfasalazine) or biologic DMARD–anti-TNF-α therapy (adalimumab, infliximab, or etanercept) alone or in combination with MTX.
↵# In most cases in combination with MTX. CDP: computerized dynamic posturography; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; MTX: methotrexate; DMARD: disease-modifying antirheumatic drug; TNF-α: tumor necrosis factor-α; N/A: not applicable.